June 2020 Issue Table Of Contents

From The Editor

• Pandemic Provides Perspective On “Virtual” Not Being Reality

Feature Articles

• How One Professor Built Two Billion-Dollar Biotechs
• A Chat On Biosimilars With Sandoz’s U.S. President Carol Lynch

Capitol Perspectives

• Assisting Millions Of Uninsured Bogged Down In Abortion Politics

CEO Corner

• Leading With Authenticity In Turbulent Times

Companies To Watch

• Companies To Watch: Spring Bank Pharmaceuticals

From Policy to Execution

• Collaborations Trump Competition During Pandemics

Patient Perspective

• Changing The Paradigm Of Drug Development To Cure Rare Disease

Industry Research

• Use Of Outside Consultants In Phase 2/3 Clinical Research

Inside The Industry

• 7 Lessons In Supply Chain Management Learned From COVID-19
• A Future-Back Approach To Transformative Therapies
• Insights Into The Competitive Clinical Manufacturing Market
• Women Shaping The Life Sciences Industry In Tampa
• A Biopharma Dealmaker’s Approach To Maximizing Strategic Partnerships

Industry Leader

• Building A Legacy With Complex Assets
• Do Biobanks Need New Strategies?

Leadership Lessons

• Leading With A Focus On Organizational Culture

Ask The Board

• How Can The Industry Effectively Partner With Health Agencies To Revamp Clinical Trials, Which Are A Major Factor For Slow/Costly Drug R&D?
• The Emerging CAR-T Therapies Are Brilliant But Appear Challenging When Trying To Reach A Large Population Of Patients. What Is The Prognosis Of Alternatives Such As Allogenic CAR-T Becoming Mainstream?
• In The Context Of Rising Clinical Trial Expenses, As A Result Of Increased Patient Numbers And Extended Time Frames, What Clinical Development Design Innovations Will We Observe In The Next Two To Five Years?